First AD

Second AD

Introducing Hypomethylating Agents for Patients With MDS

Video content above is prompted by the following:

Please provide a brief overview of hypomethylating agents for patients with intermediate- to high-risk MDS.

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Evolving Practices for Myelodysplastic Syndromes (MDS): Highlights from ASH 2024 and Beyond 

Panelists discuss how hypomethylating agents remain the cornerstone of therapy for intermediate to high-risk patients with myelodysplastic syndromes (MDS).